Share on StockTwits

Sinclair IS Pharma PLC (LON:SPH)‘s stock had its “buy” rating reaffirmed by equities researchers at FinnCap in a research report issued on Tuesday. They currently have a GBX 43 ($0.74) price target on the stock. FinnCap’s price objective indicates a potential upside of 41.62% from the company’s current price.

Shares of Sinclair IS Pharma PLC (LON:SPH) traded down 0.45% during mid-day trading on Tuesday, hitting GBX 30.3625. The stock had a trading volume of 213,311 shares. Sinclair IS Pharma PLC has a one year low of GBX 23.50 and a one year high of GBX 34.18. The stock’s 50-day moving average is GBX 30.82 and its 200-day moving average is GBX 30.81.

SPH has been the subject of a number of other recent research reports. Analysts at Oriel Securities Ltd reiterated a “buy” rating on shares of Sinclair IS Pharma PLC in a research note on Tuesday. They now have a GBX 40 ($0.68) price target on the stock. Separately, analysts at N+1 Singer reiterated a “buy” rating on shares of Sinclair IS Pharma PLC in a research note on Wednesday, May 14th. They now have a GBX 40 ($0.68) price target on the stock. Finally, analysts at N+1 Singer reiterated a “buy” rating on shares of Sinclair IS Pharma PLC in a research note on Wednesday, May 14th. They now have a GBX 40 ($0.68) price target on the stock. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of GBX 37.13 ($0.64).

Sinclair IS Pharma plc is a specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through surface technology and delivery systems.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.